Zentalis Pharmaceuticals (ZNTL) Cash & Equivalents (2019 - 2026)

Zentalis Pharmaceuticals' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $31.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 23.85% year-over-year to $31.9 million; the TTM figure through Mar 2026 stood at $31.9 million (down 23.85% YoY), while the FY2025 annual figure was $36.0 million, up 6.18% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $31.9 million, down from $36.0 million in the prior quarter.
• The five-year high for Cash & Equivalents was $266.6 million in Q2 2023, with the low at $28.0 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $37.6 million (2024), against an average of $55.8 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents surged 383.39% in 2023, then plunged 86.13% in 2024.
• Zentalis Pharmaceuticals' Cash & Equivalents stood at $43.1 million in 2022, then sank by 34.9% to $28.0 million in 2023, then gained by 20.91% to $33.9 million in 2024, then advanced by 6.18% to $36.0 million in 2025, then decreased by 11.29% to $31.9 million in 2026.
• Business Quant data shows ZNTL's Cash & Equivalents at $31.9 million in Q1 2026, $36.0 million in Q4 2025, and $39.1 million in Q3 2025.